A pivotal,Phase 3 trial of oral and intravenous formulations of MRX-1 to treat acute bacterial skin and skin structure infections (ABSSSI).
Latest Information Update: 07 Oct 2016
At a glance
- Drugs Contezolid (Primary) ; Contezolid (Primary)
- Indications Bacterial infections; Skin and soft tissue infections
- Focus Registrational; Therapeutic Use
- 07 Oct 2016 New trial record